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The function and eventual fate of immune 
cells is largely determined by factors con-
trolling their movement through distinct 
parts of our body. And the molecular basis 
for this control is provided for by chemoat-
tractants and cell adhesion molecules.
This importance of immune cell traf-
fic in immunity has not always been fully 
appreciated. In fact, cellular immunology 
has traditionally concentrated on cause–
effect relationships by, for instance, inject-
ing vaccines into mice and, after a period 
of time, removing the spleens and lymph 
nodes for extraction and in vitro analysis 
of effector cells. Mice were viewed as black 
magic  boxes  that  provided  the  essential 
inventory for allowing immune responses 
to occur. That immune cells need to “move” 
in order to achieve effector functions was 
clear.  However,  this  topic  was  regarded 
as  a  subject  of  cell  biology  rather  than 
immunology. This view definitely changed 
with the discovery of chemokines in the 
second half of the 1980s. Initially, chem-
okine  studies  focused  on  innate  immu-
nity.  Consequently,  progress  in  this  new 
field of research was discussed at Gordon 
Research Conferences on Phagocytes (and 
related meetings), alongside with “classical” 
chemoattractants such as formyl-Met-Leu-
Phe, platelet-activating factor, leukotriene 
B4,  and  complement  component  C5a. 
Combining chemokines with non-peptide 
chemoattractants made sense since they all 
act via G-protein coupled, seven transmem-
brane domains receptors (GPCR). Unlike 
non-peptide chemoattractants, chemokines 
are related in structure, both at the level of 
DNA and protein and, importantly, make 
up the largest family of cytokines. Currently, 
we know the genes for >50 chemokines and 
20 chemokine receptors. Importantly, this 
system  is  characterized  by  redundancies 
both in terms of the number of chemokines 
recognized by a single chemokine receptor 
and the number of receptors shared by indi-
vidual chemokines.
The  term  “chemokines”  stems  from 
“chemotactic cytokines” and signifies their 
prototype function “chemotaxis” of immune 
cells, i.e., their movement along a concen-
tration gradient of chemoattractants. By a 
process called “inside-out” signaling trigger-
ing of chemokine receptors induces a low-to-
high affinity shift in integrins, enabling firm 
adhesion of cells to integrin ligands present 
on other cells, such as vascular endothelial 
cells, or extracellular matrix. The former 
process  is  a  prerequisite  of  immune  cell 
extravasation and the latter process forms 
an integral part in immune cell chemotaxis. 
Both processes illustrate the intimate link 
between chemotaxis and cell adhesion. 
Rapid progress in chemokine research 
revealed that not only innate immune cells 
but all cells of the entire immune system 
respond  to  this  large  class  of  cytokines. 
The control of immune cell traffic is chal-
lenged by the considerable diversity in cell 
types, including precursor cells in the bone 
  marrow and thymus, mature immune cells 
in blood, short-lived effector T and B cells 
at sites of infections as well as immune sur-
veillance cells in healthy peripheral tissues. 
This problem is solved by the combina-
tion of distinct chemokine receptors with 
adhesion receptors, yielding precise address 
codes for guiding individual immune cell 
subsets to their target tissues. Obviously, 
mistakes in this system can cause severe 
immune  defects  with  pathophysiological 
consequences, including chronic infections 
and autoimmunity.
The  field  of  immune  cell  migration 
poses many unsolved challenges. But che-
moattractants go well beyond chemotaxis, 
as outlined in the below figure. In fact, the 
functional diversity is substantial to a degree 
that the writing of comprehensive review 
articles is a thing of the past.
The below bullet point comments illus-
trate some of the big challenges faced by 
laboratories working in this highly competi-
tive field of research.
•	 Chemokine  and  chemokine  recep-
tor  cross-talk  –  Physical  interactions 
between chemokines or between che-
mokine/chemoattractant  receptors Moser  Topics in immune cell migration
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produced by the host, and this obvious 
complexity is further expanded by viral 
products.  Investigations  are  trying  to 
make  “sense”  by  correlating  indivi-
dual  chemoattractant  systems  with 
distinct  subsets  of  effector/memory 
cells. Among other things, detailed che-
mokine receptor profiling will help to 
classify the increasing number of fun-
ctional T cell subsets.
•	 Translational  research  –  Only  two 
chemokine  receptor  antagonists 
(Maraviroc from Pfizer, and ADM3100 
from AnorMED) have recently gained 
FDA approval, but many more are in 
the pipelines. Of note, the new drugs 
do not target primarily inflammatory 
diseases. Major challenges faced by the 
pharmaceutical  industry  are  chemo-
kine redundancy, especially of those 
involved  in  inflammatory  responses, 
and GPCR cross-reactivity. Promising 
recent  compounds  target  cell  adhe-
sion  molecules  (e.g.,  α4  integrin) 
and innate chemoattractant receptors 
(e.g.,  C5aR/C5L2).  Additional  tran-
slational initiatives examine the role 
greatly  influence  their  functions  and 
contribute  to  the  fine  tuning  of  cell 
migration.
•	 Chemokine structure modifications – This 
topic deals with proteases and chemical 
modifications,  adding  an  additional 
layer  of  complexity  to  the  control  of 
chemokine function and cell migration.
•	 In situ immune cell traffic – Life ima-
ging  of  immune  cell  traffic  has  been 
instrumental  in  understanding  initia-
tion of adaptive immunity and will cer-
tainly reveal interesting novel features 
in  immune  surveillance  and  chronic 
diseases.
•	 Mechanisms  of  cell  migration  –  The 
major signaling elements that are cou-
pled to chemoattractant receptors are 
known. Now current research investi-
gates how the principal mechanisms of 
cell migration are influenced by exte-
rior factors (microbial products, neu-
rotransmitters,  cytokine  milieu)  and 
cell adhesion events.
•	 Control of innate and adaptive immu-
nity – Current activities are based on 
a  rich  inventory  of  chemoattractants 
for inhibitors of chemokines and che-
mokine transporters in inflammatory 
diseases.
The phase of chemoattractant gene dis-
covery is over. Now the Grand Challenges 
lie in the integration of the vast amount of 
information published in the past 22 years 
since work on chemokines begun in order 
to understand the precise role they play, 
together  with  the  non-peptide  chemoat-
tractants, in immunological diseases. This 
demanding objective will only be reached 
through  concerted  efforts  by  basic  bio-
medical and translational researchers across 
the globe.
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